Redica Systems
  • Login
  • Request a Demo
  • Products
    • Regulatory Intelligence
    • Inspection Intelligence
    • Site Intelligence
  • Solutions
    • Redica Systems Pharma Intelligence
    • Redica Systems MedTech Intelligence
  • Data & Services
    • Redica App
    • Catalyst
  • Company
    • About Us
    • People
    • Careers
    • Press
  • Resources
    • Blog
    • Assessments
    • Reports
    • Webinars
    • Glossary
Redica Systems
    • Regulatory Intelligence
    • Inspection Intelligence
    • Site Intelligence
    • Redica Systems Pharma Intelligence
    • Redica Systems MedTech Intelligence
    • Redica App
    • Catalyst
    • About Us
    • People
    • Careers
    • Press
    • Blog
    • Assessments
    • Reports
    • Webinars
    • Glossary
  • Login
  • Request a Demo

Resources

The Semler Complaint Against the FDA

  Semler Research Center Private Limited (Bangalore, India) is suing the FDA for requiring that sponsors repeat BA/BE studies based on the outcome of an FDA inspection that raised concerns about the trustworthiness and correctness of data. The legal complaint was filed January 18, 2018, in the US District Court Central District of California. The firm seeks […]

43 New FDA 483s | February 28th 2018

[fusion_builder_container hundred_percent=”no” equal_height_columns=”no” menu_anchor=”” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” class=”” id=”” background_color=”” background_image=”” background_position=”center center” background_repeat=”no-repeat” fade=”no” background_parallax=”none” parallax_speed=”0.3″ video_mp4=”” video_webm=”” video_ogv=”” video_url=”” video_aspect_ratio=”16:9″ video_loop=”yes” video_mute=”yes” overlay_color=”” video_preview_image=”” border_size=”” border_color=”” border_style=”solid” padding_top=”” padding_bottom=”” padding_left=”” padding_right=””][fusion_builder_row][fusion_builder_column type=”1_1″ layout=”1_1″ background_position=”left top” background_color=”” border_size=”” border_color=”” border_style=”solid” border_position=”all” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding_top=”” padding_right=”” padding_bottom=”” padding_left=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”small-visibility,medium-visibility,large-visibility” […]

GMP Regulatory Newsletter: Summary Scan | Week of 2/18/18

Laws, Regulations, Guidance, and Concept Papers The FDA issued a collection of guidance the week of February 18th regarding devices, safety, clinical ICH Quality, and administrative items. WHO and TGA each published two new guidance. It was a busy week on the publication front. Enforcement Enforcement included two warning letters, one to a device firm […]

Week of February 11th 2018 | FDA Sent These Warning Letters to Device & Pharma Companies

The FDA posted 6 warning letters this week, and we cover 5 of them below. One went to a device firm, and 4 went to finished pharmaceuticals sites, all located outside the US. Medical Devices Curasan AG (Frankfurt Germany) site received a warning letter on August 23, 2017, based on the outcome of an inspection […]

GMP Regulatory Newsletter: Summary Scan | Week of 2/11/18

Laws, Regulations, Guidance, and Concept Papers The week of February 11, 2018 was slow in the publication of guidance documents. The FDA published three, and the EMA did not publish any in the areas we follow. Health Canada and HPRA each published one item. There were also non-guidance documents and information published by EMA, MHRA, […]

Week of February 4th 2018 | FDA Sent These Warning Letters for Pharma Companies

The FDA published only seven warning letters this week. Of interest to us are two issued to finished drug manufacturers. The FDA continues their focus on OTC facilities that seemed to begin in 2017. Polaroisin International Co., Ltd. (Taiwan) received a warning letter on January 25, 2018, based on the outcome of an inspection ending […]

20,000 FDA Warning Letters

Here at FDAzilla, we’re excited to report that we have just collected our 20,000th FDA Warning Letter, going back to 2000, all completely searchable in our database.As you may know, the FDA automatically archives warning letters older than 5 years (and just did so with their 2012 collection last month). Yes it’s true: arguably, the […]

FDA Sent These 16 Warning Letters for Pharma Companies | January 2018

We took a snapshot of the 16 warning letters the FDA sent to pharmaceutical companies last month. The “Violation of the Month” was failing to bear adequate directions for the drug’s intended use. From pharmaceuticals in New Jersey, Japan, and more, here they are (starting with the most recent): Daito Kasei Kogyo Co.,Okayama,Japan – 2 violations:Failure to […]

FDA Sent These 15 Warning Letters for Pharma Companies | December 2017

We took a snapshot of the 15 warning letters (yes, 15) the FDA sent to pharmaceutical companies in December. Drug manufacturing violations ranged from failing to establish and follow adequate written procedures to failing to reveal consequences that could result from the use of a drug. From pharmaceuticals in San Diego, Korea, and more, here […]

Last 30 483s Customers Have Purchased – January 2018

We see a lot of people, all throughout the world, purchasing 483s from our FDA document store.  For example, this month customers came from Ireland, India, and China.  Here are some of the tools of the trade they purchased from us: FDA 483 Nobel Procera Services – Quebec, Canada – 12 Sep 2013 FDA 483 Catalent Pharma […]
« Older Entries
Newer Entries »
Company
  • About Redica Systems
  • People
  • Careers
  • Press
  • Contact Us
Catalyst
  • Redica Catalyst
  • Redica ID
  • Enrichment
  • Knowledge Graph
  • Redica Ontologies
Use Cases
  • For Pharma
  • For MedTech
  • Inspection Preparation
  • Vendor Quality
  • Regulatory Surveillance
Resources
  • Assessments
  • Reports
  • Webinars
  • Document Store
  • Blog
  • Glossary

© 2026 Redica. All Rights Reserved.

  • Privacy Policy
  • Terms of Use
  • Status